Previous 10 | Next 10 |
Humanigen (HGEN) fell 6% in premarket on low volume after changing the trial protocol of Phase 3 trial evaluating lenzilumab, an experimental medicine for COVID-19.More details to follow. For further details see: Humanigen `panic selling' is a buying opport...
Humanigen (HGEN) drops 8% in premarket on low volume after changing the trial protocol of Phase 3 trial evaluating lenzilumab, an experimental medicine for COVID-19.Primary endpoint for the Phase 3 trial of lenzilumab is now ventilator-free survival through day 28. The pri...
Document Security Systems (DSS) -31% on stock offering.Gevo (GEVO) -25% on stock offering.BioLineRx (BLRX) -22% on equity offering.Bionano Genomics (BNGO) -19% on pricing of stock offering.Histogen (HSTO) -12% on FDA clinical hold of planned study for HST-003.AcelRx P...
Humanigen (HGEN) partners with EVERSANA to make Lenzilumab available to hospitalized and hypoxic COVID-19 patients in the event that an Emergency Use Authorization is issued from USFDA and subsequent BLA. Humanigen’s investigational treatment, Lenzilumab, a proprietary Humaneered ...
Humanigen, Inc. (HGEN) (Humanigen), a clinical-stage biopharmaceutical company focused on preventing and treating an immune hyper-response called cytokine storm with its lead drug candidate lenzilumab™, and EVERSANA , a pioneer of next-generation services to the global li...
Humanigen, Inc . (Nasdaq: HGEN) (“Humanigen”), a clinical stage biopharmaceutical company focused on preventing and treating an immune hyper-response called ‘cytokine storm’ with its lead drug candidate, lenzilumab™, today announced that the Co...
Strong SACCOVID clinical trial results suggest an approval is forthcoming. Graft versus Host Disease linkage to the most promising therapeutics. Merck business model resonating with investors. Small pool of therapeutic drug companies represents ideal acquisition targets. ...
Universal Security Instruments (UUU) +293%.Technical Communications (TCCO) +214%.Koss Corporation (KOSS) +99%.Tenax Therapeutics (TENX) +80%.New Concept Energy (GBR) +58%.IRIDEX Corporation (IRIX) +23%.SOS Limited (SOS) +10% after announcing partnership with Zhonglu P&C Insuranc...
Gainers: ATIF Holdings (ATIF) +85%.Greenpro Capital (GRNQ) +77%.Bit Digital (BTBT) +67%.Avalon Holdings (AWX) +53%.Euro Tech Holdings Company (CLWT) +48%.Poseida Therapeutics (PSTX) +44%.Peabody Energy (BTU) +42%.Flux Power Holdings (FLUX) +39%.DPW Holdings (DPW) +37%.Marine Petroleum Trust (...
The USPTO has issued a patent to Humanigen (HGEN) for the use of lenzilumab in prevention or treatment of cytokine storm, neurotoxicity in patients undergoing chimeric antigen receptor T (CAR-T) cell therapy and inhibit or reduce incidence or severity of CAR-T-related toxicities. Th...
News, Short Squeeze, Breakout and More Instantly...
Williams Industrial Services Group Inc. (WLMSQ) is expected to report $-0.15 for Q3 2023 Cellcom Israel Limited (CELJF) is expected to report for quarter end 2023-09-30 Central Japan Railway Co ADR (CJPRY) is expected to report for Q2 2024 CW Petroleum Corp (CWPE) is expected to repor...
Strategic Environmental & Energy Resources Inc (SENR) is expected to report for Q1 2024 Biocept Inc. (BIOCQ) is expected to report for Q1 2024 Kalera Public Limited Company (KALRQ) is expected to report for quarter end 2023-09-30 Lanvin Group Holdings Limited (LANV) is expected to...
Murata Manufacturing Co. Ltd. ADR (MRAAY) is expected to report $0.27 for Q2 2024 Quotient Limited (QTNTQ) is expected to report for quarter end 2023-09-30 Evaxion Biotech A/S (EVAX) is expected to report for Q3 2023 American Virtual Cloud Technologies Inc. (AVCTQ) is expected to repo...